Yegorov's syndrome (Cerebral vasospasm) - Symptoms, Causes, Treatment & Prevention

Although vasospasm can occur after any intracranial bleeding or trauma, it is most frequently associated with subarachnoid hemorrhage. The syndrome affects adults between 40‑60 years old, with a slightly higher incidence in men (≈ 55 % of cases). Based on data from the National Inpatient Sample (2019), roughly 7–9 % of patients hospitalized for SAH develop clinically significant vasospasm, translating to about **12,000–15,000** new cases per year in the United States alone.¹

Symptoms

Symptoms of cerebral vasospasm are often delayed, appearing **3–14 days** after the inciting bleed. The clinical picture ranges from subtle changes in cognition to severe focal deficits.

Neurological symptoms

• New‑onset headache – often described as “thunderclap” or worsening “pressure” headache, different from the initial bleed.
• Altered mental status – confusion, lethargy, or difficulty concentrating.
• Focal weakness – usually unilateral (hemiparesis) affecting the arm more than the leg.
• Speech disturbances – dysarthria, aphasia, or word‑finding difficulty.
• Visual problems – diplopia, visual field cuts, or loss of peripheral vision.
• Seizures – new seizures without prior epilepsy history.

Autonomic & systemic signs

• Sudden increase in blood pressure (reflex hypertension).
• Bradycardia or irregular pulse (Cushing’s reflex).
• Nausea or vomiting not explained by other causes.

Because vasospasm may be “silent” on physical exam (especially early), clinicians rely heavily on imaging and monitoring to detect it.

Causes and Risk Factors

Cerebral vasospasm is primarily a reactive process to blood products in the subarachnoid space, but several other mechanisms contribute.

Primary triggers

• Subarachnoid hemorrhage (SAH) – rupture of a cerebral aneurysm accounts for > 85 % of cases.
• Traumatic brain injury (TBI) – especially severe closed head injuries with basal cistern blood.
• Intracerebral hemorrhage and intraventricular hemorrhage – less common but can provoke vasospasm.
• Neurosurgical procedures – clipping or coiling of aneurysms may irritate arterial walls.

Pathophysiology (simplified)

Blood breakdown products (oxy‑hemoglobin) induce a cascade of inflammation, oxidative stress, and endothelial dysfunction. This leads to:

• Release of vasoconstrictors (e.g., endothelin‑1, serotonin).
• Reduced nitric oxide availability (loss of vasodilatory tone).
• Smooth‑muscle hyper‑reactivity in arterial walls.

Risk factors that increase likelihood or severity

• Age > 50 years.
• Male sex (modest increase).
• Smoking – odds ratio ≈ 2.1 for vasospasm after SAH.²
• Hypertension and uncontrolled blood pressure.
• Large volume of subarachnoid blood (Fisher grade 3‑4 on CT).
• Presence of intraventricular hemorrhage.
• Genetic polymorphisms affecting endothelin‑1 or nitric oxide synthase (research‑stage).

Diagnosis

Because early clinical signs can be vague, a combination of bedside monitoring and imaging is essential.

Clinical monitoring

• Transcranial Doppler (TCD) ultrasonography – non‑invasive bedside tool that measures blood flow velocity in the middle cerebral artery (MCA). A mean flow velocity > 200 cm/s suggests moderate‑to‑severe vasospasm.
• Neurological examinations – performed every 2–4 hours in intensive care units (ICUs) for at‑risk patients.

Imaging studies

• CT Angiography (CTA) – quickly visualizes arterial narrowing; high sensitivity (> 90 %).
• Digital Subtraction Angiography (DSA) – gold‑standard; allows both diagnosis and endovascular treatment during the same session.
• Perfusion CT or MR perfusion – evaluates cerebral blood flow and identifies ischemic penumbra.

Laboratory markers (research)

Elevated levels of endothelin‑1 and inflammatory cytokines (IL‑6) in CSF correlate with vasospasm severity, but they are not yet routine clinical tests.

Diagnostic criteria (simplified)

1. Evidence of recent SAH or other intracranial bleed.
2. New neurological deficit or worsening headache occurring 3–14 days post‑bleed.
3. Imaging confirmation of arterial narrowing (CTA, DSA, or TCD velocity criteria).

Treatment Options

Management aims to (1) prevent spasm, (2) reverse established narrowing, and (3) protect brain tissue from ischemia.

Pharmacologic therapies

• Calcium‑channel blocker – Nimodipine (60 mg orally/NG every 4 h for 21 days). Proven to reduce delayed cerebral ischemia and improve outcomes in SAH patients (Class I recommendation).³
• Triple‑H therapy* (Hypertension, Hypervolemia, Hemodilution) – historically used to augment cerebral perfusion; now limited to selected cases due to cardiac/renal risks.
• Statins (e.g., atorvastatin 20 mg daily) – modest evidence for vasospasm reduction; beneficial for overall vascular health.
• Magnesium sulfate – intravenous loading (30 mmol) followed by infusion; data mixed, but may aid in neuroprotection.
• Endothelin‑receptor antagonist – Clazosentan – investigational; trials show decreased angiographic vasospasm but no clear functional benefit.

Endovascular procedures

• Balloon angioplasty – mechanical dilation of focally narrowed vessels; immediate effect but limited to accessible proximal arteries.
• Intra‑arterial vasodilator infusion – agents such as nicardipine, verapamil, or papaverine delivered directly to the spastic segment. Often combined with DSA.

Supportive care

• Maintain euvolemia (target CVP 4‑8 mm Hg); avoid hypovolemia.
• Control systemic blood pressure; induced hypertension (SBP 150‑180 mmHg) may be used under close monitoring.
• Seizure prophylaxis (levetiracetam) in high‑risk patients.
• Early mobilization and physical therapy once stable.

Lifestyle and adjunct measures

• Smoking cessation – reduces re‑spasm risk.
• Optimized blood pressure control with ACE inhibitors or ARBs.
• Healthy diet rich in omega‑3 fatty acids (anti‑inflammatory).

Living with Yegorov’s Syndrome (Cerebral Vasospasm)

Survivors often face ongoing neurological and psychological challenges. The following tips help maintain independence and quality of life.

Daily management

• Medication adherence – set alarms or use pill organizers for nimodipine, antihypertensives, and statins.
• Blood pressure monitoring – home cuff; aim for target set by your neurologist (usually < 140/90 mmHg unless induced hypertension is prescribed).
• Regular follow‑up imaging – CTA or MRA at 3‑month intervals in the first year, then annually if stable.
• Cognitive exercises – puzzles, memory apps, or occupational therapy to improve attention and executive function.
• Physical activity – low‑impact aerobic exercise (walking, stationary cycling) 3–5 times/week, unless contraindicated.
• Stress management – mindfulness, yoga, or counseling to reduce sympathetic surge that could provoke vasoconstriction.

When to contact your healthcare team

• New or worsening headache.
• Sudden weakness, numbness, or difficulty speaking.
• Episodes of confusion, vision changes, or seizures.
• Unexplained rise in blood pressure or swelling in the legs (possible volume overload).

Prevention

While the initial bleed cannot always be prevented, secondary prevention of vasospasm focuses on modifiable risk factors.

• Aneurysm screening – family history of intracranial aneurysms warrants MR/CTA screening at age 30‑40.
• Smoking cessation programs – counseling, nicotine replacement, or prescription meds (varenicline, bupropion).
• Blood pressure control – regular monitoring, low‑salt diet, and antihypertensive therapy.
• Limit alcohol binge drinking – excess alcohol can increase aneurysm rupture risk.
• Maintain a healthy weight – obesity is linked with hypertension and vascular inflammation.

Complications

If vasospasm is not promptly identified or treated, the following complications may arise:

• Delayed cerebral ischemia (DCI) – infarction leading to permanent motor, sensory, or language deficits.
• Stroke – both ischemic and, rarely, hemorrhagic secondary to reperfusion injury.
• Hydrocephalus – blockage of CSF pathways from blood products or edema.
• Seizure disorder – chronic epilepsy requiring long‑term antiepileptic drugs.
• Cognitive impairment – deficits in memory, attention, and executive function that affect work and daily living.
• Cardiopulmonary complications – neurogenic pulmonary edema or cardiac stunning from catecholamine surge.

When to Seek Emergency Care

© 2026 Medical Content Team. Sources: ¹ CDC National Inpatient Sample, 2019; ² Mayo Clinic, Smoking & SAH risk; ³ American Heart Association Guidelines for Subarachnoid Hemorrhage, 2023.